RESEARCHER PROFILE
Daniel Peter Petrylak
D
Yale University
Daniel Peter Petrylak works in Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Bone health and treatments. Recorded institutional associations include Yale Cancer Center, Yale University, Smilow Cancer Hospital.
834Publications
46,397Citations
88H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 · 3,665 citationsAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
2016 · 3,665 citationsPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 · 3,387 citationsMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 · 2,381 citationsAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
2016 · 2,198 citationsAvelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · 1,493 citationsEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 · 1,229 citationsARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
2019 · 1,217 citationsEligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
1999 · 977 citationsPivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019 · 642 citationsUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy
1996 · 635 citationsTROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
2021 · 542 citationsDurvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
2020 · 501 citationsRandomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
2019 · 480 citationsMeta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
2016 · 460 citationsAdjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
2021 · 429 citationsSuppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells
2012 · 416 citationsChemotherapy for advanced renal-cell carcinoma: 1983-1993.
1995 · 386 citationsTrastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial
2007 · 376 citationsMultinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
2009 · 340 citationsEV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
2020 · 338 citationsImproved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
2022 · 316 citationsDouble-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators
2007 · 312 citationsPhase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
1999 · 311 citationsAtezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
2017 · 299 citations
